Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 3/20 | 0.40 |
| ▸ | CCR1 | P32246 | 7/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5128701 | 0.97 | CCR1 (0.41) | EPHX2GRM5CCR1POLBMAPT | |
| SCHEMBL5126152 | 0.92 | ALDH1A1 (0.44) | GRM5CCR1POLBPKMALDH1A1 | |
| SCHEMBL5126144 | 0.92 | ALDH1A1 (0.44) | GRM5CCR1POLBPKMALDH1A1 | |
| Hydrochloric Acid SCHEMBL5129387 | 0.91 | ALDH1A1 (0.44) | GRM5CCR1POLBPKMALDH1A1 | |
| SCHEMBL5128421 | 0.89 | EPHX2 (0.44) | EPHX2GRM5POLBTRPV4TRPM8 | |
| SCHEMBL5128012 | 0.86 | BDKRB1 (0.43) | EPHX2CCR1POLBHSD11B1GAA | |
| SCHEMBL5121650 | 0.84 | POLB (0.43) | POLBMAPTTRPV4SMN1; SMN2 | |
| SCHEMBL3813955 | 0.84 | POLB (0.43) | POLBMAPTTRPV4SMN1; SMN2 | |
| SCHEMBL2571091 | 0.83 | PSEN1 (0.43) | GRM5 | |
| SCHEMBL3837762 | 0.83 | MEN1 (0.44) | EPHX2GRM5CCR1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | claimed |
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249128-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | EPHX2 1287/4885GRM5 994/4885CCR1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.